Observation On The Clinical Efficacy Of Juzao Pill Combined With Endocrine In The Treatment Of Advanced Prostate Cancer (blood Stasis Internal Resistance)

Objective:To observe the clinical efficacy and quality of life of the patients with advanced prostate cancer(blood stasis syndrome)treated with Juzaowan combined with endocrine therapy.Methods:31 cases of advanced prostate cancer(blood stasis syndrome)were randomly divided into the treatment group(17 cases)and the control group(14 cases).The control group was injected with a subcutaneous injection of Zoladex/one banrch each month.(acetic acid goserelin slow-release implants,astrazeneca pharmaceutical companies,3.6 mg/branch),combined with Bicalutamide 1 tablets / day,1 times / day(bicalutamide,Astra Zeneca pharmaceutical company,50mg/ tablets);the treatment group in the control group based on the service of Juzaowan 10g/ time,3 times / day,taking half an hour after a meal,two groups were treated for 6 months.Observe two groups of patients before treatment and after treatment of third months and sixth months of serum prostate specific antigen(PSA),total prostate volume changes,using the International Prostate Symptom Score(IPSS score),the quality of life instrument for EORTC(QLQ-C30)score,TCM symptoms on quality of life of patients and divided into two groups patients after endocrine therapy,the incidence rate of adverse reaction evaluation after treatment.Results:At the serum PSA level,the pretreatment level of the two groups was basically the same,with no statistical significance(P>0.05).After 3months of treatment,there were significant differences between the two groups(P<0.05)and no significant difference between the two groups(P>0.05).6 months after treatment,the treatment group compared with before 3 months after treatment,the treatment,the difference was statistically significant(P< 0.05),the control group compared with 3months,there was no significant difference(P>0.05),at the same time there are differences between the two groups(P< 0.05).There was no difference in prostate volume between the two groups before treatment.After 3 months of treatment,there was no significant difference between the two groups(P>0.05).There was no significant difference between the two groups(P>0.05).After 6 months of treatment,there was no difference between the two groups.There was a difference in the volume of prostate(P<0.05)between the two groups(P<0.05).Before treatment,there was no statistically significant difference between IPSS score,quality of life score and two groups of TCM symptom scores(P>0.05).Six months after treatment,IPSS score,quality of life score and two groups of TCM symptom scores decreased.The comparison between the two groups was statistically significant(P<0.05).Conclusion:Juzaowan combined endocrine therapy can effectively inhibit the increase of serum PSA.To reduce the volume of prostate and relieve the symptoms of lower urinary tract;It can reduce the occurrence of adverse reactions of endocrine therapy and improve the quality of life after endocrine therapy.